Sofinnova Venture Partners
Venture capitalMenlo Park · 4 people tracked
Find your way into Sofinnova Venture Partners
Fund manager profile
Sofinnova Venture Partners is a venture fund manager based in Menlo Park. SEC filings show 2 venture funds on record, most recently Sofinnova Venture Partners X, L.P. ($650M offering) filed August 2016.
Source: SEC EDGAR Form D filings. Firm website data not yet available.
Team · 4 people
from public directoriesWhat they invest in
from 9 of 9 portfolio companiesBiotech ×8Medical Devices ×5Healthtech ×4Digital Health ×2
HQs:United States×7
Investments · 9 tracked
founders shown can be your intro pathBy year:2020 · 22017 · 22015 · 15 dated
Aclaris develops investigational monoclonal antibodies and small-molecule inhibitors targeting immune pathways for the treatment of atopic, autoimmune, and respiratory diseases.
BiotechHealthtechMedical DevicesWayne, US
Neal Walker(Executive Officer, Director)Kamil Ali-Jackson(Executive Officer)Stuart D. Shanler(Executive Officer)inJoseph Monahan(Executive Officer)inHugh Davis(Executive Officer, Director)inJames Loerop(Executive Officer)
Board seatAnand Mehra· per SEC Form D · $11.4M raise · filed Apr 2020
Co-investorsAisling CapitalAPERTURE Venture PartnersF-Prime CapitalForesite CapitalRA CapitalSofinnova Ventures+1 more
Bolt Biotherapeutics is a clinical-stage biotech company developing novel immunotherapies that leverage innate immune system mechanisms to treat cancer.
BiotechHealthtechMedical DevicesSan Francisco, US
Dr. Edgar G. Engleman(Founder)
Co-investorsPfizer Venture InvestmentsRA CapitalSamsara BioCapitalSofinnova VenturesVivo CapitalNan Fung Life Sciences+3 more
Kiniksa is a global biopharmaceutical company that discovers and develops novel therapies for patients with unmet medical needs, with a focus on cardiovascular diseases and related conditions.
BiotechMedical DevicesHamilton
Sanj K. Patel(Chief Executive Officer and Chairman of the Board)RICHARD S LEVY(Director)STEPHEN R BIGGAR(Director)FELIX J BAKER(Director)THOMAS W BEETHAM(Executive Officer)THOMAS R MALLEY(Director)
Co-investorsSofinnova VenturesDeerfield Management Company
Nextcure is a clinical-stage biopharmaceutical company developing immunotherapies targeting IO pathways, with a focus on oncology applications.
BiotechBeltsville, US
Michael Richman(Executive Officer, Director)Timothy Mayer(Executive Officer)inUdayan Guha(Executive Officer)inSteven P. Cobourn(Executive Officer)inSourav Kundu(Executive Officer)inKevin Shaw(Executive Officer)in
Co-investorsBay City CapitalCanaan PartnersLAVLilly Asia VenturesPfizer Venture InvestmentsQuan Capital+4 more
Vera Therapeutics develops medicines targeting autoimmune-driven kidney diseases, with a focus on reducing the need for dialysis or transplant.
BiotechDigital HealthMedical DevicesSouth San Francisco, US
Marshall Fordyce(Executive Officer, Director)in
BoardBeth Seidenberg(Director)inMaha Katabi(Director)inKurt von Emster(Director)inPatrick Enright(Director)inAndrew Cheng(Director)
Co-investorsKleiner PerkinsLongitude CapitalSofinnova VenturesAbingworth
Iterum Therapeutics develops anti-infective compounds to treat infections caused by multi-drug resistant pathogens.
BiotechDigital HealthHealthtechMedical DevicesDublin, US
Michael W. Dunne(Executive Officer, Promoter)inCorey N. Fishman(Executive Officer, Director, Promoter)inJudith M. Matthews(Executive Officer, Promoter)Jeff Schaffnit(Executive Officer)
BoardBrenton K. Ahrens(Director)Ronald M. Hunt(Director)
Board seatJames I. Healy· per SEC Form D · $47.6M raise · filed Dec 2016
Co-investorsBay City CapitalCanaan PartnersSofinnova VenturesFrazier Life Sciences
HealthtechSan Francisco, US
Matthew F. Krummel, Ph.D.(Director)Steven P. James(Executive Officer, Director, Promoter)inLeon Chen, Ph.D.(Director)Carol Gallagher(Director)inJoshua Resnick, M.D.(Director)
Board seatMichael Powell· per SEC Form D · $62M raise · filed Dec 2017
Co-investorsMission Bay CapitalMission BiocapitalNew Enterprise Associates (NEA)OUP (Osage University Partners)Sofinnova Ventures
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Amplyx PharmaceuticalsIterum Therapeutics Bermuda
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 5
IPOs and acquisitions across the tracked portfolioAclaris TherapeuticsNASDAQ: ACRSBolt BiotherapeuticsNASDAQ: BOLTKiniksaNASDAQ: KNSANextCureNASDAQ: NXTCVeratxNASDAQ: VERA
Portfolio news
latest coverage across their companies
Veratx · manilatimes.net · Sep 1, 2026
Kiniksa · themarketsdaily.com · Jul 19, 2026
NextCure · investing.com · Jul 15, 2026
Aclaris Therapeutics · investing.com · May 8, 2026
IPO stake values · per SEC filings · 4
Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.
| Company | Owned | IPO price | At IPO | Stake value |
|---|---|---|---|---|
| NextCure | 9.4% | $36.75 | Nov 2019 | $92.7M |
| Bolt Biotherapeutics | 8.0% | $20.00 | Feb 2021 | $55.1M |
| Veratx | 11.2% | $15.00 | Feb 2022 | $43.7M |
| Kiniksa | 4.8% | $18.26 | Feb 2019 | $16.3M |
Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).
Frequently asked questions
- Where is Sofinnova Venture Partners located?
- Sofinnova Venture Partners is headquartered in Menlo Park, US.